Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer

1Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health 2019; 11: 287-99. doi: 10.2147/IJWH.S197604 Momenimovahed Z Tiznobaik A Taheri S Salehiniya H Ovarian cancer in the world: epidemiology and risk factors Int J Womens Health 2019 11 287 99 doi 10.2147/IJWH.S197604650043331118829Open DOISearch in Google Scholar

2Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017; 317: 2402-16. doi: 10.1001/jama.2017.7112 Kuchenbaecker KB Hopper JL Barnes DR Phillips K-A Mooij TM Roos-Blom MJ et al Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers JAMA 2017 317 2402 16 doi 10.1001/jama.2017.711228632866Open DOISearch in Google Scholar

3Neff RT, Senter L, Salani R. BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Ther Adv Med Oncol 2017; 9: 519-31. doi: 10.1200/JCO.2003.01.068 Neff RT Senter L Salani R BRCA mutation in ovarian cancer: testing, implications and treatment considerations Ther Adv Med Oncol 2017 9 519 31 doi 10.1200/JCO.2003.01.06812743135Open DOISearch in Google Scholar

4Bast RC Jr. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003; 21(10 Suppl): 200s-5s. doi: 10.1200/JCO.2003.01.068 Bast RCJr Status of tumor markers in ovarian cancer screening J Clin Oncol 2003 2110 Suppl 200s 5s doi 10.1200/JCO.2003.01.068Open DOISearch in Google Scholar

5Yawn BP, Barrette BA, Wollan PC. Ovarian cancer: the neglected diagnosis. Mayo Clin Proc 2004; 79: 1277-82. doi: 10.4065/79.10.1277 Yawn BP Barrette BA Wollan PC Ovarian cancer: the neglected diagnosis Mayo Clin Proc 2004 79 1277 82 doi 10.4065/79.10.127715473410Open DOISearch in Google Scholar

6Bottoni P, Scatena R. The role of CA 125 as tumor marker: biochemical and clinical aspects. Adv Exp Med Biol 2015; 867: 229-44. doi: 10.1007/978-94017-7215-0_14 Bottoni P Scatena R The role of CA 125 as tumor marker: biochemical and clinical aspects Adv Exp Med Biol 2015 867 229 44 doi 10.1007/978-94017-7215-0_14Open DOISearch in Google Scholar

7Yang WL, Lu Z, Bast RC. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn 2017; 17: 577-91. doi: 10.1080/14737159.2017 Yang WL Lu Z Bast RC The role of biomarkers in the management of epithelial ovarian cancer Expert Rev Mol Diagn 2017 17 577 91 doi 10.1080/14737159.2017Open DOISearch in Google Scholar

8Sundar S, Neal RD, Kehoe S. Diagnosis of ovarian cancer. BMJ 2015; 351: h4443. doi: https://doi.org/10.1136/bmj.h4443 Sundar S Neal RD Kehoe S Diagnosis of ovarian cancer BMJ 2015 351 h4443 doi https://doi.org/10.1136/bmj.h444310.1136/bmj.h444326328593Search in Google Scholar

9Elies A, Rivière S, Pouget N, Becette V, Dubot C, Donnadieu A, et al. The role of neoadjuvant chemotherapy in ovarian cancer. Expert Rev Anticancer Ther 2018; 18: 555-66. doi: 10.1080/14737140.2018.1458614 Elies A Rivière S Pouget N Becette V Dubot C Donnadieu A et al The role of neoadjuvant chemotherapy in ovarian cancer Expert Rev Anticancer Ther 2018 18 555 66 doi 10.1080/14737140.2018.145861429633903Open DOISearch in Google Scholar

10du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 2009; 115: 1234-44. doi: 10.1002/cncr.24149 du Bois A Reuss A Pujade-Lauraine E Harter P Ray-Coquard I Pfisterer J Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO) Cancer 2009 115 1234 44 doi 10.1002/cncr.2414919189349Open DOISearch in Google Scholar

11Arab M, Jamdar F, Sadat Hosseini M, Ghodssi-Ghasemabadi R, Farzaneh F, Ashrafganjoie T. Model for prediction of optimal debulking of epithelial ovarian cancer. Asian Pac J Cancer Prev 2018; 19: 1319-24. doi: 10.22034/ APJCP.2018.19.5.1319 Arab M Jamdar F Sadat Hosseini M Ghodssi-Ghasemabadi R Farzaneh F Ashrafganjoie T Model for prediction of optimal debulking of epithelial ovarian cancer Asian Pac J Cancer Prev 2018 19 1319 24 doi 10.22034/APJCP.2018.19.5.1319603181129802693Open DOISearch in Google Scholar

12Vorgias G, Iavazzo C, Savvopoulos P, Myriokefalitaki E, Katsoulis M, Kalinoglou N, et al. Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study. Gynecol Oncol 2009; 112: 11-5. doi: 10.1016/j.ygyno.2008.09.020 Vorgias G Iavazzo C Savvopoulos P Myriokefalitaki E Katsoulis M Kalinoglou N et al Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study Gynecol Oncol 2009 112 11 5 doi 10.1016/j.ygyno.2008.09.02019119502Open DOISearch in Google Scholar

13Kang S, Kim TJ, Nam BH, Seo SS, Kim BG, Bae DS, et al. Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. J Surg Oncol 2010; 101: 13-7. doi: 10.1002/jso.21398 Kang S Kim TJ Nam BH Seo SS Kim BG Bae DS et al Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis J Surg Oncol 2010 101 13 7 doi 10.1002/jso.2139820025071Open DOISearch in Google Scholar

14Chi DS, Zivanovic O, Palayekar MJ, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol 2009; 112: 6-10. doi: 10.1016/j.ygyno.2008.10.010 Chi DS Zivanovic O Palayekar MJ Eisenhauer EL Abu-Rustum NR Sonoda Y et al A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma Gynecol Oncol 2009 112 6 10 doi 10.1016/j.ygyno.2008.10.01019100916Open DOISearch in Google Scholar

15Rodriguez N, Rauh-Hain JA, Shoni M, Berkowitz RS, Muto MG, Feltmate C, et al. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol 2012; 125: 362-6. doi: 10.1016/j.ygyno.2012.02.006 Rodriguez N Rauh-Hain JA Shoni M Berkowitz RS Muto MG Feltmate C et al Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy Gynecol Oncol 2012 125 362 6 doi 10.1016/j.ygyno.2012.02.00622333992Open DOISearch in Google Scholar

16Pelissier A, Bonneau C, Chéreau E, de La Motte Rouge T, Fourchotte V, Daraï E, et al. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol 2014; 135: 542-6. doi: 10.1016/j.ygyno.2014.09.005 Pelissier A Bonneau C Chéreau E de La Motte Rouge T Fourchotte V Daraï E et al CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy Gynecol Oncol 2014 135 542 6 doi 10.1016/j.ygyno.2014.09.00525223808Open DOISearch in Google Scholar

17Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2016; 34: 3460-73. doi: 10.1200/JCO.2016.68.6907 Wright AA Bohlke K Armstrong DK Bookman MA Cliby WA Coleman RL et al Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline J Clin Oncol 2016 34 3460 73 doi 10.1200/JCO.2016.68.6907551259427502591Open DOISearch in Google Scholar

18Orr B, Edwards RP. Diagnosis and treatment of ovarian cancer. Hematol Oncol Clin North Am 2018; 32: 943-64. doi: 10.1016/j.hoc.2018.07.010 Orr B Edwards RP Diagnosis and treatment of ovarian cancer Hematol Oncol Clin North Am 2018 32 943 64 doi 10.1016/j.hoc.2018.07.01030390767Open DOISearch in Google Scholar

19Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol 2017; 28(Suppl 8): viii61-5. doi: 10.1093/annonc/mdx443 Eisenhauer EA Real-world evidence in the treatment of ovarian cancer Ann Oncol 2017 28Suppl 8 viii61 5 doi 10.1093/annonc/mdx44329232466Open DOISearch in Google Scholar

20Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-53. doi: 10.1056/NEJMoa0908806 Vergote I Tropé CG Amant F Kristensen GB Ehlen T Johnson N et al Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 2010 363 943 53 doi 10.1056/NEJMoa090880620818904Open DOISearch in Google Scholar

21Schwartz PE. Neoadjuvant chemotherapy for the management of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2002; 16: 585-96. doi: 10.1053/ beog.2002.0304 Schwartz PE Neoadjuvant chemotherapy for the management of ovarian cancer Best Pract Res Clin Obstet Gynaecol 2002 16 585 96 doi 10.1053/beog.2002.030412413936Open DOISearch in Google Scholar

22Morice P, Dubernard G, Rey A, Atallah D, Pautier P, Pomel C, et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg 2003; 197: 955-63. doi: 10.1016/j.jamcollsurg.2003.06.004 Morice P Dubernard G Rey A Atallah D Pautier P Pomel C et al Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer J Am Coll Surg 2003 197 955 63 doi 10.1016/j.jamcollsurg.2003.06.00414644284Open DOISearch in Google Scholar

23Pecorelli S, Odicino F, Favalli G. Interval debulking surgery in advanced epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2002; 16: 573-83. doi: 10.1053/beog.2002.0302 Pecorelli S Odicino F Favalli G Interval debulking surgery in advanced epithelial ovarian cancer Best Pract Res Clin Obstet Gynaecol 2002 16 573 83 doi 10.1053/beog.2002.030212413935Open DOISearch in Google Scholar

24Zeng J, Yin J, Song X, Jin Y, Li Y, Pan L. Reduction of CA125 levels during neo-adjuvant chemotherapy can predict cytoreduction to no visible residual disease in patients with advanced epithelial ovarian cancer, primary carcinoma of fallopian tube and peritoneal carcinoma. J Cancer 2016; 7: 2327-32. doi: 10.7150/jca.16761 Zeng J Yin J Song X Jin Y Li Y Pan L Reduction of CA125 levels during neo-adjuvant chemotherapy can predict cytoreduction to no visible residual disease in patients with advanced epithelial ovarian cancer, primary carcinoma of fallopian tube and peritoneal carcinoma J Cancer 2016 7 2327 32 doi 10.7150/jca.16761516654427994671Open DOISearch in Google Scholar

25Mahdi H, Maurer KA, Nutter B, Rose PG. The impact of percent reduction in CA-125 levels on prediction of the extent of interval cytoreduction and outcome in patients with advanced-stage cancer of Müllerian origin treated with neoadjuvant chemotherapy: Int J Gynecol Cancer 2015; 25: 823-9. doi: 10.1097/IGC.0000000000000434 Mahdi H Maurer KA Nutter B Rose PG The impact of percent reduction in CA-125 levels on prediction of the extent of interval cytoreduction and outcome in patients with advanced-stage cancer of Müllerian origin treated with neoadjuvant chemotherapy Int J Gynecol Cancer 2015 25 823 9 doi 10.1097/IGC.000000000000043425828750Open DOISearch in Google Scholar

26Gupta M, Patel SM, Arora R, Tiwari R, Dave P, Desai A, et al. Does preoperative CA-125 cutoff value and percent reduction in CA-125 levels correlate with surgical and survival outcome after neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer? – Our experience from a tertiary cancer institute. South Asian J Cancer 2020; 9: 30. doi: 10.4103/sajc. sajc_53_17 Gupta M Patel SM Arora R Tiwari R Dave P Desai A et al Does preoperative CA-125 cutoff value and percent reduction in CA-125 levels correlate with surgical and survival outcome after neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer? – Our experience from a tertiary cancer institute South Asian J Cancer 2020 9 30 doi 10.4103/sajc.sajc_53_17695657331956617Open DOISearch in Google Scholar

27Kessous R, Wissing MD, Piedimonte S, Abitbol J, Kogan L, Laskov I, et al. CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer. Acta Obstet Gynecol Scand 2020; 99: 933-40. doi: 10.1111/aogs.13814 Kessous R Wissing MD Piedimonte S Abitbol J Kogan L Laskov I et al CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer Acta Obstet Gynecol Scand 2020 99 933 40 doi 10.1111/aogs.1381431954071Open DOISearch in Google Scholar

28Mueller JJ, Zhou QC, Iasonos A, O’Cearbhaill RE, Alvi FA, El Haraki A, et al. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol Oncol 2016; 140: 436-42. doi: 10.1016/j.ygyno.2016.01.008 Mueller JJ Zhou QC Iasonos A O’Cearbhaill RE Alvi FA El Haraki A et al Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center Gynecol Oncol 2016 140 436 42 doi 10.1016/j.ygyno.2016.01.008476758726777991Open DOISearch in Google Scholar

29Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386: 249-57. doi: 10.1016/S0140-6736(14)62223-6 Kehoe S Hook J Nankivell M Jayson GC Kitchener H Lopes T et al Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial Lancet 2015 386 249 57 doi 10.1016/S0140-6736(14)62223-626002111Open DOISearch in Google Scholar

30Mahner S, Trillsch F, Chi D, Harter P, Pfisterer J, Hilpert F, et al. Neoadjuvant chemotherapy in ovarian cancer revisited. Ann Oncol 2016; 27(Suppl 1): i30-2. doi: 10.1093/annonc/mdw092 Mahner S Trillsch F Chi D Harter P Pfisterer J Hilpert F et al Neoadjuvant chemotherapy in ovarian cancer revisited Ann Oncol 2016 27Suppl 1 i30 2 doi 10.1093/annonc/mdw09227141067Open DOISearch in Google Scholar

31Machida H, Tokunaga H, Matsuo K, Matsumura N, Kobayashi Y, Tabata T, et al. Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol 2020; 46: 868-75. doi: 10.1016/j.ejso.2019.11.520 Machida H Tokunaga H Matsuo K Matsumura N Kobayashi Y Tabata T et al Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: a systematic review and meta-analysis Eur J Surg Oncol 2020 46 868 75 doi 10.1016/j.ejso.2019.11.520753513131818526Open DOISearch in Google Scholar

32du Bois A, Baert T, Vergote I. Role of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. J Clin Oncol 2019; 37: 2398-405. doi: 10.1200/JCO.19.00022 du Bois A Baert T Vergote I Role of neoadjuvant chemotherapy in advanced epithelial ovarian cancer J Clin Oncol 2019 37 2398 405 doi 10.1200/JCO.19.0002231403864Open DOISearch in Google Scholar